Corcept Therapeutics (NASDAQ:CORT) Stock: Insider Roberto Wandenkolk Vieira Sells 8,333 Shares

Posted by Brian Himes on Nov 6th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Roberto Vieira sold 8,333 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $80.89, for a total transaction of $674,056.37. Following the completion of the transaction, the insider owned 3,946 shares of the company’s stock, valued at approximately $319,191.94. The trade was a 67.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Roberto Wandenkolk Vieira also recently made the following trade(s):

On Friday, October 2nd, Roberto Vieira sold 8,333 shares of Corcept Therapeutics stock. The shares were sold at an average price of $116.10, for a total transaction of $967,461.30.
On Wednesday, September 16th, Roberto Vieira sold 296 shares of Corcept Therapeutics stock. The stock was sold at an average price of $100.82, for a total transaction of $29,842.72.
On Wednesday, September 2nd, Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08.

Corcept Therapeutics Stock Down 9.6%

Shares of NASDAQ:CORT opened at $71.63 on Friday. The company’s fifty day moving average is $108.46 and its two-hundred day moving average is $75.47. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $126.38. The company has a market cap of $7.84 billion, a P/E ratio of 56.40 and a beta of 0.54.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.84 by $0.17. The business had revenue of $340.47 million during the quarter, compared to analysts’ expectations of $339.12 million. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. Corcept Therapeutics’s revenue was up 64.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.16 earnings per share. Equities research analysts anticipate that Corcept Therapeutics Incorporated will post 1.83 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Corcept Therapeutics during the 2nd quarter worth about $1,080,964,000. First Trust Advisors LP grew its holdings in Corcept Therapeutics by 213.5% in the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Corcept Therapeutics in the 2nd quarter worth approximately $49,185,000. Bank of America Corp DE bought a new position in Corcept Therapeutics in the 2nd quarter worth approximately $28,569,000. Finally, Legal & General Group Plc acquired a new position in shares of Corcept Therapeutics during the second quarter worth approximately $18,962,000. 93.61% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CORT shares. HC Wainwright reaffirmed a “buy” rating and set a $165.00 price objective on shares of Corcept Therapeutics in a research report on Friday, September 18th. Zacks Research cut shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a report on Monday, July 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $173.00 target price (up from $165.00) on shares of Corcept Therapeutics in a research report on Wednesday. Finally, Truist Financial began coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price target for the company. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $139.50.

Get Our Latest Stock Report on CORT

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

Positive Sentiment: Third-quarter revenue climbed 64% year over year to about $340.5 million, while earnings of $1.01 per share beat estimates. Higher Korlym sales and growing Lifyorli uptake contributed to the results. Article: CORT’s Q3 Earnings Beat
Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $173 from $165. Article: Piper Sandler rating
Neutral Sentiment: Corcept is awaiting a December 17 FDA decision on relacorilant and has outlined a long-term opportunity of $3 billion to $5 billion in Cushing’s revenue by 2030; both depend on regulatory and commercial success. Article: Relacorilant decision and revenue target
Negative Sentiment: Shares have faced pressure despite the earnings beat as investors focused on company guidance. HC Wainwright also lowered its Q1 2027 EPS estimate to $0.60 from $0.74, although it kept a Buy rating and $165 price target. Article: Shares fall on guidance
Negative Sentiment: Two insiders reported sizable sales: Roberto Vieira sold 8,333 shares, reducing his position by about 68%, while Sean Maduck sold shares in two transactions that cut his holdings by more than half. Insider sales can raise concerns, though they do not necessarily indicate a change in company prospects. Article: Corcept insider sale

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.